Impact of "No-touch" Technique on the Outcome of Liver Transplantation for Hepatocellular Carcinoma

The "no-touch" technique has been one of the most important principles of oncological surgery and aimed to prevent seeding and tumor cell dissemination. Previous studies in hepatectomy have shown that no-touch technique surgery can reduce HCC recurrence and improve the survival of patients. However, there is no consensus on whether the no-touch technique in LT for HCC improves the outcomes. This study aims to prospectively include liver transplant patients from multiple transplant centers, collecting their pre-transplant clinical information, post-transplant pathological records and exploring and clarify the correlation between "no-touch" technique and the prognosis of LT patients.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Liver Transplantation Adenocarcinoma Carcinoma Carcinoma, Hepatocellular Digestive System Diseases Digestive System Neoplasms Hepatocellular Carcinoma Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial No-touch Technique

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of HCC based on CT or MRI imaging or needle biopsy confirming a histologic diagnosis of HCC.
Patients undergoing deceased donor liver transplantation for the first time.

Exclusion criteria

(1) patients who received split LT or simultaneous transplantation, (2) patients who received re-transplantation, (3) patients with macroscopic portal vein tumor thrombosis or other macrovascular invasion, (4) patients with incomplete follow-up or incomplete important parameters records.

Treatment and study plan

Liver transplantation with "No-touch" technique

Procedure

The core principle of "no-touch" tumor surgery revolves around avoiding direct contact with the tumor or surrounding tissues as much as possible to minimize the release of cancer cells into the bloodstream or nearby tissues.

Primary outcomes

Recurrence free surviavl rate

Time frame: 2024.4.1-2028.4.1
Overall survival rate

Time frame: 2024.4.1-2028.4.1
Tumor recurrence rate

Time frame: 2024.4.1-2028.4.1

Sponsors and collaborators

Lead sponsor

Zhejiang University

Other

Collaborators

Shulan (Hangzhou) Hospital

Registry information

Important dates

Study start: 2024
Primary completion: 2028
Study completion: 2028
First posted: Mar 26, 2024
Registry last updated: Mar 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting